| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 27 | 2023 | 839 | 4.900 |
Why?
|
| Tissue Donors | 12 | 2022 | 195 | 3.950 |
Why?
|
| Liver Transplantation | 17 | 2022 | 400 | 3.880 |
Why?
|
| Tissue and Organ Procurement | 13 | 2022 | 164 | 3.870 |
Why?
|
| Kidney Failure, Chronic | 9 | 2023 | 365 | 3.330 |
Why?
|
| Carcinoma, Hepatocellular | 9 | 2017 | 163 | 3.260 |
Why?
|
| Liver Neoplasms | 10 | 2017 | 334 | 3.170 |
Why?
|
| Chemoembolization, Therapeutic | 7 | 2017 | 16 | 3.110 |
Why?
|
| Decision Making | 6 | 2019 | 410 | 2.020 |
Why?
|
| Organ Transplantation | 5 | 2022 | 110 | 1.830 |
Why?
|
| Tacrolimus | 8 | 2023 | 127 | 1.710 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2020 | 767 | 1.700 |
Why?
|
| Patient Selection | 9 | 2021 | 592 | 1.420 |
Why?
|
| Hepatectomy | 6 | 2016 | 58 | 1.370 |
Why?
|
| Graft Survival | 10 | 2022 | 465 | 1.340 |
Why?
|
| Graft Rejection | 10 | 2020 | 458 | 1.300 |
Why?
|
| Healthcare Disparities | 4 | 2023 | 378 | 1.280 |
Why?
|
| Middle Aged | 47 | 2021 | 21147 | 1.230 |
Why?
|
| Retrospective Studies | 32 | 2022 | 7277 | 1.210 |
Why?
|
| Alabama | 10 | 2020 | 98 | 1.190 |
Why?
|
| Immunosuppressive Agents | 8 | 2020 | 514 | 1.180 |
Why?
|
| Male | 61 | 2021 | 37321 | 1.170 |
Why?
|
| Aged | 37 | 2021 | 14862 | 1.100 |
Why?
|
| Hernia, Ventral | 5 | 2007 | 35 | 1.090 |
Why?
|
| Female | 55 | 2021 | 38074 | 1.080 |
Why?
|
| Adult | 44 | 2023 | 21403 | 1.060 |
Why?
|
| Motivation | 5 | 2020 | 561 | 1.030 |
Why?
|
| Humans | 78 | 2023 | 68618 | 1.010 |
Why?
|
| Radiosurgery | 2 | 2016 | 66 | 0.970 |
Why?
|
| Family | 2 | 2019 | 293 | 0.950 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2016 | 59 | 0.940 |
Why?
|
| Health Services Accessibility | 4 | 2020 | 581 | 0.920 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2016 | 536 | 0.840 |
Why?
|
| Motor Vehicles | 2 | 2019 | 20 | 0.800 |
Why?
|
| Health Policy | 2 | 2021 | 221 | 0.790 |
Why?
|
| Living Donors | 5 | 2022 | 160 | 0.790 |
Why?
|
| Cholangiocarcinoma | 3 | 2016 | 20 | 0.780 |
Why?
|
| Liver Cirrhosis | 2 | 2014 | 301 | 0.750 |
Why?
|
| Vascular Surgical Procedures | 3 | 2017 | 168 | 0.740 |
Why?
|
| United States Government Agencies | 1 | 2020 | 4 | 0.720 |
Why?
|
| Television | 1 | 2020 | 28 | 0.710 |
Why?
|
| Automobile Driving | 2 | 2020 | 88 | 0.700 |
Why?
|
| Waiting Lists | 6 | 2022 | 104 | 0.700 |
Why?
|
| Bile Duct Neoplasms | 2 | 2016 | 39 | 0.690 |
Why?
|
| Time Factors | 12 | 2020 | 4655 | 0.680 |
Why?
|
| Transplant Recipients | 3 | 2022 | 109 | 0.670 |
Why?
|
| Postoperative Complications | 9 | 2019 | 1615 | 0.670 |
Why?
|
| Video Recording | 1 | 2020 | 145 | 0.660 |
Why?
|
| Attitude to Health | 2 | 2014 | 403 | 0.650 |
Why?
|
| Abdominal Wall | 4 | 2007 | 20 | 0.650 |
Why?
|
| Licensure | 1 | 2018 | 18 | 0.640 |
Why?
|
| Liver Diseases | 2 | 2012 | 193 | 0.620 |
Why?
|
| Wound Healing | 6 | 2006 | 260 | 0.610 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 468 | 0.600 |
Why?
|
| Abdominal Muscles | 3 | 2007 | 25 | 0.590 |
Why?
|
| Health Education | 1 | 2020 | 279 | 0.590 |
Why?
|
| Aged, 80 and over | 11 | 2021 | 4848 | 0.590 |
Why?
|
| Treatment Outcome | 17 | 2018 | 7029 | 0.570 |
Why?
|
| Hospitalization | 2 | 2020 | 978 | 0.550 |
Why?
|
| United States | 15 | 2022 | 7367 | 0.520 |
Why?
|
| Models, Statistical | 1 | 2019 | 448 | 0.510 |
Why?
|
| Cold Ischemia | 1 | 2015 | 5 | 0.500 |
Why?
|
| Glomerular Filtration Rate | 4 | 2020 | 274 | 0.500 |
Why?
|
| Transportation | 1 | 2015 | 21 | 0.500 |
Why?
|
| Policy Making | 1 | 2015 | 51 | 0.490 |
Why?
|
| Organizational Policy | 1 | 2015 | 42 | 0.490 |
Why?
|
| Heart Failure | 2 | 2022 | 1180 | 0.480 |
Why?
|
| Shock, Hemorrhagic | 1 | 2014 | 33 | 0.470 |
Why?
|
| Brain Death | 1 | 2014 | 34 | 0.470 |
Why?
|
| Chi-Square Distribution | 5 | 2016 | 546 | 0.460 |
Why?
|
| Medicaid | 1 | 2016 | 302 | 0.460 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 711 | 0.460 |
Why?
|
| Proportional Hazards Models | 8 | 2017 | 792 | 0.460 |
Why?
|
| Young Adult | 11 | 2021 | 5717 | 0.450 |
Why?
|
| Professional-Family Relations | 1 | 2013 | 45 | 0.440 |
Why?
|
| Specialization | 1 | 2013 | 66 | 0.440 |
Why?
|
| Multidetector Computed Tomography | 1 | 2013 | 60 | 0.440 |
Why?
|
| Risk Factors | 13 | 2019 | 5731 | 0.430 |
Why?
|
| Renal Dialysis | 3 | 2023 | 174 | 0.430 |
Why?
|
| Venae Cavae | 2 | 2009 | 16 | 0.420 |
Why?
|
| Medically Uninsured | 1 | 2013 | 99 | 0.420 |
Why?
|
| Hospital Costs | 2 | 2017 | 117 | 0.420 |
Why?
|
| Insurance Coverage | 1 | 2013 | 99 | 0.410 |
Why?
|
| Social Class | 1 | 2012 | 127 | 0.410 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 504 | 0.410 |
Why?
|
| Peritoneovenous Shunt | 1 | 2011 | 1 | 0.410 |
Why?
|
| Logistic Models | 6 | 2017 | 1420 | 0.400 |
Why?
|
| Focus Groups | 3 | 2019 | 247 | 0.400 |
Why?
|
| Ascites | 1 | 2011 | 38 | 0.400 |
Why?
|
| Fatty Liver | 1 | 2012 | 97 | 0.400 |
Why?
|
| Vena Cava, Superior | 1 | 2011 | 41 | 0.390 |
Why?
|
| Insurance, Health | 1 | 2013 | 201 | 0.390 |
Why?
|
| Registries | 6 | 2022 | 733 | 0.390 |
Why?
|
| Catheters, Indwelling | 1 | 2011 | 72 | 0.390 |
Why?
|
| Follow-Up Studies | 7 | 2019 | 3259 | 0.380 |
Why?
|
| Catheterization, Central Venous | 1 | 2011 | 89 | 0.370 |
Why?
|
| Cohort Studies | 7 | 2022 | 2358 | 0.370 |
Why?
|
| Survival Rate | 5 | 2015 | 1056 | 0.370 |
Why?
|
| Cholangitis | 1 | 2010 | 15 | 0.350 |
Why?
|
| Surveys and Questionnaires | 6 | 2019 | 2800 | 0.350 |
Why?
|
| Vascular Neoplasms | 1 | 2009 | 15 | 0.350 |
Why?
|
| Eosinophilia | 1 | 2010 | 47 | 0.340 |
Why?
|
| Self Concept | 1 | 2010 | 132 | 0.340 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2016 | 2324 | 0.340 |
Why?
|
| Body Image | 1 | 2010 | 100 | 0.330 |
Why?
|
| Necrosis | 3 | 2014 | 239 | 0.330 |
Why?
|
| Femoral Vein | 1 | 2009 | 15 | 0.330 |
Why?
|
| Resource Allocation | 3 | 2019 | 35 | 0.330 |
Why?
|
| Hypothermia, Induced | 1 | 2009 | 93 | 0.330 |
Why?
|
| Liposarcoma | 1 | 2009 | 13 | 0.330 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2009 | 12 | 0.330 |
Why?
|
| Perception | 1 | 2010 | 189 | 0.330 |
Why?
|
| Multivariate Analysis | 5 | 2016 | 1046 | 0.320 |
Why?
|
| Predictive Value of Tests | 5 | 2014 | 1465 | 0.320 |
Why?
|
| Catheter Ablation | 1 | 2010 | 229 | 0.310 |
Why?
|
| Calcineurin Inhibitors | 1 | 2008 | 24 | 0.310 |
Why?
|
| Renal Insufficiency | 2 | 2020 | 121 | 0.310 |
Why?
|
| Ureteroscopy | 1 | 2007 | 5 | 0.300 |
Why?
|
| Adolescent | 10 | 2021 | 8912 | 0.300 |
Why?
|
| Cyclosporine | 1 | 2008 | 121 | 0.300 |
Why?
|
| Stents | 2 | 2013 | 657 | 0.300 |
Why?
|
| Sirolimus | 1 | 2008 | 118 | 0.290 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2016 | 446 | 0.290 |
Why?
|
| Health Resources | 1 | 2007 | 76 | 0.290 |
Why?
|
| Rats, Sprague-Dawley | 8 | 2007 | 2083 | 0.290 |
Why?
|
| Prognosis | 4 | 2019 | 2093 | 0.280 |
Why?
|
| Incidence | 6 | 2021 | 1603 | 0.280 |
Why?
|
| Dermatofibrosarcoma | 2 | 2004 | 8 | 0.280 |
Why?
|
| Surgical Wound Dehiscence | 2 | 2004 | 20 | 0.280 |
Why?
|
| Mental Health | 1 | 2009 | 278 | 0.280 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 2279 | 0.280 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2008 | 161 | 0.260 |
Why?
|
| Educational Status | 3 | 2012 | 273 | 0.260 |
Why?
|
| Income | 3 | 2012 | 167 | 0.260 |
Why?
|
| Risk Assessment | 4 | 2019 | 2007 | 0.260 |
Why?
|
| Collagen | 3 | 2006 | 636 | 0.250 |
Why?
|
| Disease-Free Survival | 3 | 2016 | 349 | 0.250 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2004 | 48 | 0.250 |
Why?
|
| Cost of Illness | 2 | 2021 | 206 | 0.250 |
Why?
|
| Mohs Surgery | 1 | 2004 | 16 | 0.240 |
Why?
|
| Quality of Life | 2 | 2010 | 1515 | 0.230 |
Why?
|
| Rats | 8 | 2007 | 5300 | 0.230 |
Why?
|
| Odds Ratio | 3 | 2016 | 880 | 0.220 |
Why?
|
| Drug Administration Schedule | 3 | 2020 | 567 | 0.220 |
Why?
|
| Calcitonin | 1 | 2003 | 21 | 0.220 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2023 | 22 | 0.220 |
Why?
|
| Wounds, Penetrating | 1 | 2003 | 45 | 0.220 |
Why?
|
| Delayed-Action Preparations | 2 | 2019 | 120 | 0.220 |
Why?
|
| Stomach Diseases | 1 | 2003 | 22 | 0.220 |
Why?
|
| Treatment Failure | 1 | 2003 | 216 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 2 | 2016 | 369 | 0.210 |
Why?
|
| Age Factors | 2 | 2020 | 1864 | 0.210 |
Why?
|
| Kidney Function Tests | 2 | 2019 | 114 | 0.210 |
Why?
|
| Surgical Procedures, Operative | 1 | 2003 | 124 | 0.200 |
Why?
|
| Transplants | 1 | 2022 | 28 | 0.200 |
Why?
|
| Delayed Graft Function | 2 | 2022 | 39 | 0.200 |
Why?
|
| Skin Neoplasms | 2 | 2004 | 375 | 0.200 |
Why?
|
| Cause of Death | 2 | 2013 | 241 | 0.200 |
Why?
|
| Cholecystectomy | 2 | 2016 | 79 | 0.200 |
Why?
|
| Stress, Physiological | 1 | 2003 | 215 | 0.190 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 1054 | 0.190 |
Why?
|
| Wounds and Injuries | 1 | 2004 | 334 | 0.190 |
Why?
|
| Reoperation | 3 | 2012 | 467 | 0.190 |
Why?
|
| Self Efficacy | 1 | 2021 | 199 | 0.180 |
Why?
|
| Phlebography | 2 | 2011 | 31 | 0.180 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2020 | 26 | 0.180 |
Why?
|
| Length of Stay | 4 | 2018 | 780 | 0.180 |
Why?
|
| Attitude to Death | 1 | 2020 | 52 | 0.180 |
Why?
|
| Pancreaticojejunostomy | 1 | 2000 | 21 | 0.180 |
Why?
|
| Histocompatibility Testing | 1 | 2020 | 38 | 0.170 |
Why?
|
| Donor Selection | 1 | 2020 | 29 | 0.170 |
Why?
|
| Health Care Costs | 4 | 2018 | 346 | 0.170 |
Why?
|
| Nursing Care | 1 | 2019 | 18 | 0.170 |
Why?
|
| Fibroblasts | 1 | 2004 | 902 | 0.170 |
Why?
|
| Costs and Cost Analysis | 1 | 2020 | 193 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 2 | 2014 | 504 | 0.170 |
Why?
|
| Death | 1 | 2019 | 38 | 0.170 |
Why?
|
| Tablets | 1 | 2019 | 19 | 0.170 |
Why?
|
| Metabolic Clearance Rate | 1 | 2019 | 48 | 0.170 |
Why?
|
| Capsules | 1 | 2019 | 18 | 0.160 |
Why?
|
| Biological Availability | 1 | 2019 | 79 | 0.160 |
Why?
|
| Personal Satisfaction | 2 | 2010 | 123 | 0.160 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 242 | 0.160 |
Why?
|
| Kidney | 4 | 2022 | 945 | 0.160 |
Why?
|
| Area Under Curve | 1 | 2019 | 238 | 0.160 |
Why?
|
| Principle-Based Ethics | 1 | 2018 | 3 | 0.160 |
Why?
|
| Urologic Diseases | 2 | 2008 | 11 | 0.160 |
Why?
|
| Disease Models, Animal | 4 | 2007 | 2550 | 0.150 |
Why?
|
| Employment | 2 | 2009 | 154 | 0.150 |
Why?
|
| Anastomosis, Surgical | 2 | 2009 | 104 | 0.150 |
Why?
|
| Health Status Disparities | 2 | 2018 | 326 | 0.150 |
Why?
|
| Forecasting | 1 | 2019 | 277 | 0.150 |
Why?
|
| Pancreatitis | 1 | 2000 | 279 | 0.150 |
Why?
|
| Iliac Artery | 1 | 2017 | 44 | 0.150 |
Why?
|
| Induction Chemotherapy | 1 | 2017 | 39 | 0.150 |
Why?
|
| Psychological Theory | 1 | 2017 | 27 | 0.150 |
Why?
|
| Attitude | 1 | 2018 | 121 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 148 | 0.140 |
Why?
|
| Health Care Rationing | 1 | 2017 | 32 | 0.140 |
Why?
|
| Liver Failure | 2 | 2014 | 27 | 0.140 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 694 | 0.140 |
Why?
|
| Propensity Score | 1 | 2016 | 117 | 0.140 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2016 | 34 | 0.140 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2016 | 33 | 0.140 |
Why?
|
| Fascia | 3 | 2004 | 17 | 0.140 |
Why?
|
| SEER Program | 1 | 2016 | 153 | 0.140 |
Why?
|
| Sex Factors | 1 | 2020 | 1266 | 0.140 |
Why?
|
| HIV Long-Term Survivors | 1 | 2016 | 2 | 0.130 |
Why?
|
| Postoperative Period | 1 | 2016 | 238 | 0.130 |
Why?
|
| Collagen Type III | 2 | 2006 | 21 | 0.130 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2015 | 5 | 0.130 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2017 | 87 | 0.130 |
Why?
|
| Qualitative Research | 1 | 2017 | 369 | 0.130 |
Why?
|
| Neoplasm Staging | 2 | 2011 | 800 | 0.130 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 172 | 0.130 |
Why?
|
| End Stage Liver Disease | 1 | 2016 | 60 | 0.130 |
Why?
|
| Patient Readmission | 3 | 2018 | 267 | 0.120 |
Why?
|
| Collagen Type I | 2 | 2006 | 175 | 0.120 |
Why?
|
| Animals | 8 | 2007 | 20881 | 0.120 |
Why?
|
| Retreatment | 1 | 2014 | 59 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2016 | 714 | 0.120 |
Why?
|
| Hepatitis C | 1 | 2016 | 114 | 0.120 |
Why?
|
| Medicare | 1 | 2016 | 319 | 0.120 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 955 | 0.120 |
Why?
|
| Tensile Strength | 2 | 2004 | 90 | 0.120 |
Why?
|
| Referral and Consultation | 3 | 2022 | 383 | 0.120 |
Why?
|
| Tumor Burden | 1 | 2014 | 132 | 0.120 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2014 | 125 | 0.120 |
Why?
|
| Biomechanical Phenomena | 2 | 2006 | 368 | 0.120 |
Why?
|
| Neovascularization, Physiologic | 2 | 2006 | 164 | 0.120 |
Why?
|
| Fatal Outcome | 1 | 2014 | 164 | 0.120 |
Why?
|
| Liver Function Tests | 1 | 2014 | 114 | 0.110 |
Why?
|
| Double-Balloon Enteroscopy | 1 | 2013 | 4 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2023 | 3705 | 0.110 |
Why?
|
| Dilatation | 1 | 2013 | 58 | 0.110 |
Why?
|
| Cholestasis | 1 | 2013 | 90 | 0.110 |
Why?
|
| Marital Status | 1 | 2012 | 65 | 0.110 |
Why?
|
| Telemedicine | 1 | 2020 | 700 | 0.100 |
Why?
|
| Policy | 2 | 2022 | 58 | 0.100 |
Why?
|
| Feasibility Studies | 1 | 2014 | 652 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 234 | 0.100 |
Why?
|
| Nitric Oxide | 1 | 2014 | 382 | 0.100 |
Why?
|
| Equipment Failure | 1 | 2011 | 112 | 0.100 |
Why?
|
| Radiography, Interventional | 1 | 2011 | 49 | 0.100 |
Why?
|
| Residence Characteristics | 1 | 2012 | 252 | 0.090 |
Why?
|
| Equipment Design | 1 | 2011 | 500 | 0.090 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2013 | 348 | 0.090 |
Why?
|
| Common Bile Duct | 1 | 2010 | 22 | 0.090 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2010 | 20 | 0.090 |
Why?
|
| Leiomyosarcoma | 1 | 2009 | 17 | 0.090 |
Why?
|
| Hepatic Veins | 1 | 2009 | 13 | 0.090 |
Why?
|
| Patient Dropouts | 1 | 2010 | 98 | 0.090 |
Why?
|
| Histocytochemistry | 1 | 2010 | 149 | 0.090 |
Why?
|
| Tissue Preservation | 1 | 2009 | 44 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2014 | 1040 | 0.090 |
Why?
|
| Microscopy | 1 | 2010 | 64 | 0.090 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2010 | 76 | 0.090 |
Why?
|
| Statistics, Nonparametric | 2 | 2007 | 306 | 0.090 |
Why?
|
| Neurilemmoma | 1 | 2009 | 26 | 0.090 |
Why?
|
| Reperfusion | 1 | 2009 | 78 | 0.090 |
Why?
|
| Intraoperative Care | 1 | 2009 | 91 | 0.080 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2009 | 30 | 0.080 |
Why?
|
| Biopsy | 1 | 2011 | 540 | 0.080 |
Why?
|
| Endosonography | 1 | 2010 | 177 | 0.080 |
Why?
|
| Transplantation, Autologous | 1 | 2009 | 145 | 0.080 |
Why?
|
| Antimetabolites | 1 | 2008 | 17 | 0.080 |
Why?
|
| Health Surveys | 1 | 2010 | 489 | 0.080 |
Why?
|
| Renal Replacement Therapy | 1 | 2008 | 40 | 0.080 |
Why?
|
| HIV Infections | 1 | 2016 | 791 | 0.080 |
Why?
|
| Ureter | 1 | 2007 | 16 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2008 | 3187 | 0.070 |
Why?
|
| Utilization Review | 1 | 2007 | 48 | 0.070 |
Why?
|
| Creatinine | 1 | 2008 | 243 | 0.070 |
Why?
|
| Growth Substances | 2 | 2006 | 77 | 0.070 |
Why?
|
| Compliance | 1 | 2007 | 26 | 0.070 |
Why?
|
| Urinary Tract Infections | 1 | 2007 | 71 | 0.070 |
Why?
|
| Biomarkers | 1 | 2012 | 1593 | 0.070 |
Why?
|
| Anticoagulants | 1 | 2009 | 356 | 0.070 |
Why?
|
| Counseling | 1 | 2009 | 280 | 0.070 |
Why?
|
| Muscular Atrophy | 1 | 2007 | 35 | 0.070 |
Why?
|
| Laparotomy | 1 | 2007 | 65 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 649 | 0.070 |
Why?
|
| Health Status | 1 | 2009 | 429 | 0.070 |
Why?
|
| Elasticity | 1 | 2006 | 103 | 0.070 |
Why?
|
| Suture Techniques | 1 | 2006 | 75 | 0.070 |
Why?
|
| Veins | 1 | 2006 | 68 | 0.070 |
Why?
|
| Surgical Mesh | 1 | 2006 | 57 | 0.070 |
Why?
|
| Gallbladder Diseases | 1 | 2005 | 16 | 0.060 |
Why?
|
| Regeneration | 1 | 2006 | 105 | 0.060 |
Why?
|
| Fibrosis | 1 | 2007 | 371 | 0.060 |
Why?
|
| Neutrophils | 1 | 2006 | 204 | 0.060 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 125 | 0.060 |
Why?
|
| Drug Implants | 1 | 2004 | 19 | 0.060 |
Why?
|
| Base Sequence | 1 | 2006 | 1015 | 0.060 |
Why?
|
| Disease Progression | 1 | 2008 | 1038 | 0.060 |
Why?
|
| Stress, Mechanical | 1 | 2005 | 208 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1745 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2008 | 1553 | 0.060 |
Why?
|
| Intensive Care Units | 2 | 2018 | 344 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2004 | 129 | 0.060 |
Why?
|
| Drug Carriers | 1 | 2004 | 90 | 0.060 |
Why?
|
| Child | 3 | 2008 | 6405 | 0.060 |
Why?
|
| Recurrence | 1 | 2006 | 948 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 191 | 0.060 |
Why?
|
| Sex Distribution | 1 | 2004 | 274 | 0.060 |
Why?
|
| Injections, Intraventricular | 1 | 2003 | 50 | 0.050 |
Why?
|
| Age Distribution | 1 | 2004 | 320 | 0.050 |
Why?
|
| Universities | 2 | 2018 | 191 | 0.050 |
Why?
|
| In Vitro Techniques | 1 | 2004 | 765 | 0.050 |
Why?
|
| Cytoprotection | 1 | 2003 | 39 | 0.050 |
Why?
|
| Gastrointestinal Motility | 1 | 2003 | 52 | 0.050 |
Why?
|
| Kinetics | 1 | 2004 | 1047 | 0.050 |
Why?
|
| Restraint, Physical | 1 | 2003 | 59 | 0.050 |
Why?
|
| Polymers | 1 | 2004 | 244 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2006 | 1664 | 0.050 |
Why?
|
| Heart Transplantation | 1 | 2005 | 328 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1174 | 0.050 |
Why?
|
| Acute Disease | 1 | 2003 | 658 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 951 | 0.050 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2022 | 102 | 0.050 |
Why?
|
| Heart Atria | 1 | 2022 | 206 | 0.050 |
Why?
|
| Genotype | 1 | 2023 | 786 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 1753 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2004 | 1174 | 0.040 |
Why?
|
| Massachusetts | 1 | 2019 | 28 | 0.040 |
Why?
|
| North Carolina | 1 | 2020 | 224 | 0.040 |
Why?
|
| Blood Loss, Surgical | 1 | 2000 | 79 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2022 | 705 | 0.040 |
Why?
|
| Echocardiography | 1 | 2022 | 515 | 0.040 |
Why?
|
| Benchmarking | 1 | 2019 | 91 | 0.040 |
Why?
|
| Efficiency, Organizational | 1 | 2019 | 61 | 0.040 |
Why?
|
| Infant | 2 | 2008 | 2891 | 0.040 |
Why?
|
| Liver | 2 | 2017 | 1118 | 0.040 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 77 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 352 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2020 | 230 | 0.040 |
Why?
|
| Beneficence | 1 | 2018 | 9 | 0.040 |
Why?
|
| Medical Staff | 1 | 2018 | 5 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 442 | 0.040 |
Why?
|
| Stakeholder Participation | 1 | 2018 | 17 | 0.040 |
Why?
|
| Muromonab-CD3 | 1 | 2017 | 8 | 0.040 |
Why?
|
| Alemtuzumab | 1 | 2017 | 10 | 0.040 |
Why?
|
| Body Weight | 1 | 2000 | 554 | 0.040 |
Why?
|
| Hepatic Artery | 1 | 2017 | 25 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 248 | 0.040 |
Why?
|
| Antilymphocyte Serum | 1 | 2017 | 52 | 0.040 |
Why?
|
| Collateral Circulation | 1 | 2017 | 34 | 0.040 |
Why?
|
| Mortality | 1 | 2018 | 163 | 0.040 |
Why?
|
| Adolescent Behavior | 1 | 2019 | 264 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2016 | 15 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 33 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 151 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2017 | 376 | 0.030 |
Why?
|
| Coinfection | 1 | 2016 | 30 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1342 | 0.030 |
Why?
|
| Students, Medical | 1 | 2018 | 210 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 481 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 511 | 0.030 |
Why?
|
| Platelet Transfusion | 1 | 2014 | 21 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2017 | 374 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1196 | 0.030 |
Why?
|
| Allografts | 1 | 2014 | 63 | 0.030 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2013 | 15 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2016 | 419 | 0.030 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2013 | 9 | 0.030 |
Why?
|
| Erythrocyte Transfusion | 1 | 2014 | 72 | 0.030 |
Why?
|
| South Carolina | 1 | 2019 | 2752 | 0.030 |
Why?
|
| Catheterization | 1 | 2013 | 209 | 0.030 |
Why?
|
| Morbidity | 1 | 2010 | 130 | 0.020 |
Why?
|
| Psychology | 1 | 2009 | 36 | 0.020 |
Why?
|
| Canada | 1 | 2009 | 267 | 0.020 |
Why?
|
| Inflammation | 1 | 2014 | 1030 | 0.020 |
Why?
|
| Medical Records | 1 | 2007 | 121 | 0.020 |
Why?
|
| Neutropenia | 1 | 2006 | 72 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2006 | 145 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2006 | 160 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2004 | 44 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2009 | 659 | 0.010 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2004 | 19 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2004 | 86 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2008 | 2455 | 0.010 |
Why?
|
| Models, Animal | 1 | 2004 | 252 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2004 | 384 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 866 | 0.010 |
Why?
|